Leading the Fight
Against Solid Tumors

About Us

Pioneering Novel Approaches
to Deliver on the Promise of TILs


At Turnstone, our mission is to develop new medicines to treat and cure patients with solid tumors.

Solid tumors present a major burden to society, with high mortality and poor outcomes associated with more advanced disease. Approved immunotherapies represent a significant advancement in the treatment of solid tumors, but many patients either do not respond or experience relapsed disease following an initial response. We believe the most significant challenge to creating curative immunotherapies in these patients is the low numbers of T cells that can recognize and attack the tumor, which we refer to as tumor‑reactive T cells.

To address this problem, we are pioneering a differentiated approach to tumor infiltrating lymphocytes, or TILs. We are developing next-generation TIL therapies by selecting the most potent (meaning able to mediate an anti-tumor response) and tumor-reactive T cells, which we refer to as Selected TILs. We are developing next-generation TIL therapies for potential treatment across multiple solid tumors.

Leadership

Experienced Team of
Leaders and Innovators

Turnstone has assembled a seasoned management team, an accomplished Board of Directors and a distinguished Scientific Advisory Board whose contributions to science have meaningfully advanced the field and helped inform our understanding of the relationship between cancer and the immune system.

Our passionate team of leaders comprises world-renowned professionals with deep expertise in TILs, cell therapy, tumor immunology, innate and adaptive immunity, oncolytic viruses, and in the discovery and development, manufacturing, and business and commercial development of complex biologics.

sammy-bg

Sammy Farah, PhD, MBA

President & Chief Executive Officer
steward-bg

Stewart Abbot, PhD

Chief Scientific Officer
saryah-bg

Saryah Azmat

Chief Business Officer
mike-turnstone

Mike Burgess, MBChB, PhD

Interim Chief Medical Officer
Vijay Chiruvolu

Vijay Chiruvolu, PhD

Interim Chief Technology Officer
venkat-bg

Venkat Ramanan, PhD

Chief Financial Officer
stojd

David Stojdl, PhD

SVP, Discovery Research
chad

Chad Green, PhD

SVP, Technical Operations
langer

TJ Langer

SVP, Cell Therapy Development and External Innovation
adina

Adina Pelusio

SVP, Clinical Operations
Karen Major new

Karen Major

VP, Regulatory
george

George Smith, MBA, PhD

VP, Cell Therapy Business Operations
jerel-1

Jerel Davis, PhD

Chairman & Director
Versant Ventures
mike

Mike Burgess, MBChB, PhD

Executive Director
Turnstone Biologics
sammy

Sammy Farah, PhD, MBA

Director
Turnstone Biologics
robert

Robert Gould, PhD

Director
Fulcrum Therapeutics
rishi-1

Rishi Gupta, JD

Director
OrbiMed
Kanya_R

Kanya Rajangam, MD, PhD

Director
Senti Biosciences
william-waddill

William Waddill

Director
Former CFO Calithera Biosciences, OncoMed, and Ilypsa
jeff

Jeff Courtney

In Memoriam

Our Approach

Next-Generation Approaches
with Selected TIL Therapy

Turnstone is pioneering a differentiated approach to tumor infiltrating lymphocytes, or TILs. We are developing next-generation TIL therapies by selecting the most potent (meaning able to mediate an anti-tumor response) and tumor-reactive T cells, which we refer to as Selected TILs. Unlike other approaches that rely on standard “bulk TILs” that have demonstrated objective responses in clinical trials only in limited tumor types, we are developing our Selected TILs for potential treatment across the majority of solid tumors.

Tumor infiltrating lymphocytes (TILs) are a type of cell therapy that harness the patient’s own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient’s tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient. TILs have the ability to penetrate, recognize, and kill cancer cells and offer potential to treat or cure solid tumors.

Turnstone’s next-generation Selected TILs have the potential for treatment of multiple solid tumors. Our innovative Selected TIL approach focuses on selecting and expanding the most potent tumor-reactive T cells to overcome the limitations of bulk TILs. This approach is grounded in work conducted in academia that demonstrated improved clinical responses for Selected TILs in solid tumors. We are leveraging this work to establish a standardized manufacturing process for large scale production of our Selected TILs.

Our Selected TIL approach employs the following foundational principles with the goal of yielding the greatest number and proportion of tumor-reactive T cells in our TIL products:

  • Unbiased identification of patient-specific tumor antigens.

    We seek to identify the most comprehensive set of patient-specific tumor antigens. We use an unbiased identification process that aims to find and capture the greatest diversity of antigens with the potential to drive the most robust T cell response. Our proprietary approach is unlike other TIL products that are biased toward a specific subset or class of antigen(s), which may miss relevant tumor antigens or focus on the wrong targets.

  • Selection of greatest breadth of tumor-reactive T cells from patient extracted TILs.

    Our goal is to capture and isolate the greatest number and proportion of a patient’s tumor-reactive T cells that have the potential to attack and destroy heterogeneous solid tumors.  We aim to select the greatest diversity of T cells by using a function-based screening process that confirms reactivity to the identified patient-specific tumor antigens rather than relying on a bioinformatics-based prediction algorithm that may not be truly predictive.

  • Expansion of tumor-reactive T cells and removal of non-tumor-reactive bystander cells.

    We expand our selected tumor-reactive TIL population to magnitudes consistent with bulk TIL products and actively remove unnecessary bystander cells. This selective expansion resulted in a substantially higher proportion of tumor-reactive T cells in the final product, which we believe will result in targeted tumor killing.

Selected TIL Therapy diagram

Our Superior Killing Virus, or SKV Vaccinia, is derived from the Copenhagen strain of vaccinia that exhibits powerful oncolytic activity in human tumors and we have engineered the viral backbone to develop a highly potent viral immunotherapy. The SKV Vaccinia backbone modifications were specifically designed and selected to support:

  • Enhanced immune activation through removal of immunosuppressive genes
  • Highly selective tumor targeting for increased potency and safety
  • Delivery of multiple transgenes to encode for specific functions
  • Optimized viral spread and infection in the tumor
  • Systemic and intra-tumoral (IT) administration

RIVAL-01, our lead clinical stage viral immunotherapy program, being developed in partnership with Takeda, utilizes the inherent activity of the SKV Vaccinia backbone and includes a rationally selected payload combination designed to further drive oncolytic and immune-mediated killing of the tumor. The three key payloads encoded in RIVAL-01 include:

  • Flt3L, a growth factor to support the differentiation and expansion of highly relevant antigen-presenting dendritic cells which are critical for anti-tumor immune response
  • IL-12, a pro-inflammatory cytokine to promote T-cell cytotoxicity, activate innate immune cells and minimize immunosuppression
  • Anti-CTLA-4, an antibody that inhibits CTLA-4-mediated immunosuppression and downregulation of T-cell activation

We believe that Turnstone is strongly positioned to be a leader in leveraging viral immunotherapy to further increase the activity of our TIL therapies, if approved.

Viral immunotherapy is a therapeutic modality with widespread potential to drive and modulate immune responses to solid tumors. Many viruses have inherent oncolytic activity that can be modulated through genetic engineering. These viruses preferentially infect, replicate within, and kill malignant tumor cells, and can induce broad immune responses. Viral immunotherapies are designed to convert immunologically unresponsive “cold” tumor microenvironments to more reactive “hot” tumor microenvironments and thereby enhance the activity of other immunotherapies.

We are initially evaluating viral immunotherapies in combination with our lead Selected TIL product candidate, TIDAL-01, via two approaches:

  • Administration of virus prior to TIL extraction to optimize TIL harvest and broaden applicability to additional tumor types with low immune cell infiltration, and
  • Administration of virus following treatment with TIDAL-01 to optimize TIL trafficking and infiltration into solid tumors and to support the anti-tumor functions of infiltrating immune cells.
TIL virus diagram - July 2023

Scientific Resources

Explore academic selection strategies that have demonstrated clinical proof of concept, relevant to Turnstone’s differentiated approach to TIL therapy:


Learn more about our scientific and clinical research, and the potential of Turnstone’s Selected TIL therapy in a broad range of solid tumors:

Pipeline

Designed to Shift the Paradigm
for the Treatment of Solid Tumors

We are applying our Selected TIL approach for the potential treatment of a wide range of solid tumors. We are developing a broad pipeline aimed at improving outcomes for patients with cancers, as illustrated in the chart below.

Program Product Overview Key Indications Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone
Selected TILs
TIDAL-01 Tumor-reactive
Selected TILs
Breast Cancer,
CRC,
HNSCC,
Uveal melanoma
+
Clinical program update in mid-2024
CRC,
Cutaneous and non-cutaneous melanomas,
HNSCC
+
Moffitt Collaboration*
Combination with
viral immunotherapy
Solid tumors
IND submission
TIDAL-02 Selected TILs with next-
gen manufacturing and
TIL quality enhancements
Solid tumors
IND submission
Selected TILs
PreclinicalPhase 1Phase 2Phase 3

TIDAL-01

Tumor-reactive Selected TILs
Breast Cancer, CRC, HNSCC, Uveal Melanoma

+

TIDAL-01

Tumor-reactive selected TILs
CRC, Cutaneous and non-cutaneous melanomas, HNSCC

Moffitt Logo
+

TIDAL-01

Combination with viral immunotherapy
Solid tumors

TIDAL-02

Selected TILs with next-gen manufacturing and TIL quality enhancements
Solid tumors

*Two concurrent investigator-sponsored trials at Moffitt Cancer Center
CRC = Colorectal cancer; HNSCC = Head and neck squamous cell carcinoma

Partners

Optimizing Technological Innovations
Through Strategic Partnerships

We are backed by successful top-tier life science and biotech investors committed to Turnstone’s growth, and have forged select collaborations with key academic institutions, major biopharmaceutical companies, elite researchers and prominent international cancer medical centers to support the development of our next-generation Selected TIL and immunotherapy pipeline.

Together with our strategic partners, we are devoted to delivering transformative therapies to the millions of cancer patients underserved by current treatment options.

Key Collaborators

National Cancer Institute (NCI)

In November 2022, Turnstone announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to study TIL therapy in novel combinations with viral immunotherapy.

Moffitt Logo

In July 2022, Turnstone announced a strategic alliance with Moffitt Cancer Center focused on the development of Turnstone’s pipeline of tumor-reactive selected TILs targeting solid tumors.

CRCHUM Logo

In April 2022, Turnstone announced a TIL therapy research collaboration with CRCHUM to develop novel strategies for tumor-reactive T-cell selection in Turnstone’s TIL therapy candidates against solid tumor indications.

News

Careers

Empowering Our People
to Drive Science Forward

Turnstone is committed to true innovation, fearless execution and operational excellence. Our team work with an unrelenting sense of urgency to fulfill our mission. Our decision-making is driven by bold science and our therapeutics are designed with the patient at the forefront of our thoughts.

We continue to build a values-driven organization that embraces diversity, equity, and recognizes that the sum of our parts drives more success than any single individual. Our talented people and deeply ingrained culture are vital elements in maintaining our competitive edge in the vast biotech universe and key to unlocking the full potential of cancer immunotherapy.

If you are passionate about making a difference for patients and are excited by our mission and science, Turnstone might just be for you.

Team Opportunities

Turnstone Biologics (“Turnstone”), a public clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone’s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing time to treatment for patients. The Company has an ongoing Phase 1 trial in solid tumors for the lead TIL therapy candidate, TIDAL-01, and a Phase 1 trial in partnership with the Moffitt Cancer Center.

At Turnstone, the science drives decision-making and our therapeutics are designed with the patient foremost in mind. We continue to build a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding thereafter are what we call ‘another day at Turnstone’? If you are a passionate person, and our science excites you – this opportunity may be for you.

 

Summary:

We are seeking a highly effective, self-motivated, and versatile Supply Chain professional with demonstrated knowledge and experience in the biotechnology/ pharmaceutical industry. As a Supply Chain Manager at Turnstone you will have an incredible opportunity to partner with internal and external resources to ensure supply of product to clinical trial patients. You will be responsible for ensuring materials are available for both Manufacturing and Clinical Trial sites. Additionally, you will have the opportunity to lead and/or support key sourcing and procurement initiatives to onboard new suppliers. You also will work with cross-functional teams to identify and implement improvements within the end-to-end Supply Plan. This role is critical to enable manufacturing and clinical operations and support the advancement of Turnstone’s pipeline. This role provides support remotely across all domestic time zones and reports into the Sr. Director of Supply Chain.

 

Responsibilities:

  • Inventory Management and Procurement
  • Material Resource Planning
  • Master Data and Bill of Material accuracy
  • Supplier Management
  • Sourcing and Supplier onboarding
  • Cross-functional Project Management
  • Continuous Improvement / Operational Excellence

Education and Experience:

  • 5+ years of Supply Chain experience in the biotechnology/pharmaceutical industry.  Specific experience in Cell and Gene therapy preferred but not required.
  • Bachelor’s degree in Science, Engineering, or Business.
  • Master’s degree in Science, Engineering, or Business, preferred but not required.
  • Strong interpersonal, teamwork, and organizational skills; effective oral and written communication skills.
  • Leadership and staff development experience
  • Continuous Improvement mindset with experience in Lean, Six-Sigma, PDCA or similar
  • Experience with ERP and/or other electronic systems to manage supply planning, material requirements, and inventory.
  • Experience in Materials Management and Procurement to manage inventory and ensure supply.
  • Solid understanding of the full end-to-end Supply Chain processes (plan, source, make and deliver).
  • Highly proficient at leveraging data to develop insights and identify improvement opportunities.
  • Demonstrated ability to manage multiple tasks/projects with aggressive timelines.
  • Occasional travel as required to attend workshops, strategy/planning sessions, or supplier visits.

COMPENSATION

At Turnstone, we prioritize the well-being and success of our team. Join us and enjoy a competitive compensation package, including a base salary and performance-based bonuses. Our comprehensive benefits include:

 

  • Healthcare Coverage: Medical, dental, and vision insurance for you and your dependents.
  • Retirement Planning: 401(k) plan with employer contributions.
  • Time Off: Generous paid time off, including vacation, sick leave, and holidays.
  • Workplace Flexibility: Flexible schedules and remote work options.

To Apply:

Please click here to apply!

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

 

 

Turnstone Biologics (“Turnstone”), a public clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone’s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing time to treatment for patients. The Company has an ongoing Phase 1 trial in solid tumors for the lead TIL therapy candidate, TIDAL-01, and a Phase 1 trial in partnership with the Moffitt Cancer Center.

At Turnstone, the science drives decision-making and our therapeutics are designed with the patient foremost in mind. We continue to build a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding thereafter are what we call ‘another day at Turnstone’? If you are a passionate person, and our science excites you – this opportunity may be for you.

Summary:

We are seeking a highly effective, self-motivated Scientist to join our Analytical Development team at Turnstone Biologics. In this role, you will contribute to the advancement of our cell therapy programs, particularly in developing next-generation T-cell therapies for solid tumors. The ideal candidate will be responsible for developing, qualifying, and implementing analytical methods for drug product (DP) and in-process sample characterization with minimal guidance. Key responsibilities include designing and conducting experiments, analyzing, and interpreting results, and communicating findings in team meetings. Additionally, the role requires collaboration with internal and external partners, including CDMO and CRO. The position is an onsite, lab-based role in La Jolla, CA, with responsibilities as an individual contributor, reporting to the Director of Analytical Development.

Responsibilities:

  • Contribute to the development, optimization, qualification, and transfer of analytical assays, including potency and phenotypic profiling for both lot release and characterization of cell therapy products.
  • Design and execute assays and characterization studies to interrogate immune cell biology and function with minimal assistance.
  • Plan, coordinate, and execute analytical testing using multi-parametric flow cytometry, ELISA/Ella/MSD, and molecular methods.
  • Collaborate cross-functionally and support routine Process Development (PD) sample testing and other internal/external studies supporting regulatory submission.
  • Document laboratory procedures and experiments with great attention to detail, including Electronic Lab Notebook (ELN) record keeping.
  • Support method transfer to partners at external contract manufacturing organizations, including compilation of documentation (protocols, test methods, reports).
  • Develop, revise, approve, and own SOPs (Standard Operating Procedures) and technical (transfer, validation, bridging, etc.) protocols / reports.
  • Analyze data, prepare reports and data packages for communicating with key stakeholders, senior management, and external partners.
  • Willingness to travel to external partner locations for method‑related support, when necessary.
  • Additional duties as assigned.

Education and Experience:

  • MS with 4+ years OR PhD in Biology with 1+ years of Analytical Development experience.
  • Hands-on experience with flow cytometry and ELISA-based assay development optimization, and troubleshooting is required.
  • Experience with cell-based potency assessment and functional characterization of drug products is desired.
  • Strong technical acumen, with a keen eye for detail in data analysis and record-keeping skills.
  • Basic understanding of ICH guidelines for assay qualification/validation.
  • Experience with data analysis such as GraphPad Prism, FlowJo and JMP.
  • Comfortable in a fast-paced environment with minimal direction and able to adjust workload based upon changing priorities.
  • Self-motivated, detail-oriented, and willing to accept temporary responsibilities outside of initial job description.
  • Demonstrated ability to manage multiple tasks/projects with demanding timelines.
  • Strong interpersonal, teamwork, and organizational skills; effective oral and written communication skills.
  • Occasional travel to support cross-functional workshops or strategy/planning activities.

COMPENSATION

At Turnstone, we prioritize the well-being and success of our team. Join us and enjoy a competitive compensation package, including a base salary and performance-based bonuses. Our comprehensive benefits include:

  • Healthcare Coverage: Medical, dental, and vision insurance for you and your dependents.
  • Retirement Planning: 401(k) plan with employer contributions.
  • Time Off: Generous paid time off, including vacation, sick leave, and holidays.
  • Workplace Flexibility: Flexible schedules and remote work options.

To Apply:

Please click here to apply!

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

 

 

Turnstone Biologics (“Turnstone”), a public clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone’s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing time to treatment for patients. The Company has an ongoing Phase 1 trial in solid tumors for the lead TIL therapy candidate, TIDAL-01, and a Phase 1 trial in partnership with the Moffitt Cancer Center.

At Turnstone, the science drives decision-making and our therapeutics are designed with the patient foremost in mind. We continue to build a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding thereafter are what we call ‘another day at Turnstone’? If you are a passionate person, and our science excites you – this opportunity may be for you.

Summary:

We are seeking a highly effective, self-motivated Senior Scientist to join our Analytical Development team at Turnstone Biologics. In this role, you will contribute to the advancement of our cell therapy programs, particularly in developing next-generation T-cell therapies for solid tumors. The ideal candidate will be responsible for innovating, designing, developing, troubleshooting, and implementing analytical methods. Key responsibilities include independently designing and conducting experiments, analyzing, and interpreting results, and effectively communicating findings in team meetings. Additionally, the role requires collaboration with internal and external partners, including CDMO and CRO. This position is suited for someone who is passionate about cell therapy and thrives in a fast-paced, collaborative environment. The successful candidate will also perform qualification/validation and tech transfer of assays, routine testing of drug product (DP) and in-process samples. The position is an onsite, lab-based role in La Jolla, CA, with responsibilities as an individual contributor, reporting to the Director of Analytical Development.

Responsibilities:

  • Independently design, develop, optimize, troubleshoot, and qualify analytical methods to support drug product (DP) release and characterization ensuring technical excellence.
  • Evaluate new and innovative technologies for determining drug product potency and product/process impurities.
  • Plan and execute routine DP testing activities, including in-process and stability samples, using flow cytometry and ELISA/Ella to support regulatory submissions.
  • Lead assay transfer to external partners and training analysts.
  • Author, review and own test methods/SOPs, qualification protocols, and technical reports in accordance with regulatory guidelines.
  • Document laboratory procedures and experiments with great attention to detail, including Electronic Lab Notebook (ELN) record keeping.
  • Analyze data, prepare reports and data packages for communicating with key stakeholders, senior management, and external partners.
  • Coordinate tasks across functions, demonstrating prioritization and planning skills.
  • Present work to key stakeholders and leadership.
  • Provide assistance and mentorship to junior team members.
  • Willingness to travel to external partner locations for method‑related support, when necessary.
  • Additional duties as assigned.

Education and Experience:

  • Ph.D. in Biology with at least 4+ years of relevant industry experience.
  • Strong preference for candidates with experience in immuno-oncology with a focus on engineered T cells and/or other immune cell types.
  • Proficiency in a wide range of analytical techniques, including but not limited to multi-parametric flow cytometry, ELISA/MSD, and qPCR/ddPCR.
  • Experience in multi-color flow cytometry analyses, including panel design and data analysis is essential.
  • Experience in developing cell-based potency assay will be a plus.
  • Ability to work in a highly adaptive environment and learn new skills for changing priorities.
  • Knowledge of cGMP and regulatory guidelines (e.g., FDA, EMA) and a track record of ensuring compliance in analytical operations.
  • Good understanding of ICH guidelines for assay qualification/validation.
  • Basic understanding of method lifecycle management from development to validation and beyond.
  • Ability to analyze and interpret data and contextualize with the program goals and requirements in a phase-appropriate manner.
  • Demonstrated resilience, influence, relationship-building, and problem-solving skills in a variety of situations.
  • Experience managing, mentoring, and engaging direct reports is a plus.
  • Self-motivated, detail-oriented, and willing to accept temporary responsibilities outside of initial job description.
  • Demonstrated ability to manage multiple tasks/projects with demanding timelines.
  • Strong interpersonal, teamwork, and organizational skills; effective oral and written communication skills.
  • Occasional travel to support cross-functional workshops or strategy/planning activities.

COMPENSATION

At Turnstone, we prioritize the well-being and success of our team. Join us and enjoy a competitive compensation package, including a base salary and performance-based bonuses. Our comprehensive benefits include:

  • Healthcare Coverage: Medical, dental, and vision insurance for you and your dependents.
  • Retirement Planning: 401(k) plan with employer contributions.
  • Time Off: Generous paid time off, including vacation, sick leave, and holidays.
  • Workplace Flexibility: Flexible schedules and remote work options.

To Apply:

Please click here to apply!

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

 

 

Turnstone Biologics (“Turnstone”), a public clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone’s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing time to treatment for patients. The Company has an ongoing Phase 1 trial in solid tumors for the lead TIL therapy candidate, TIDAL-01, and a Phase 1 trial in partnership with the Moffitt Cancer Center.

At Turnstone, the science drives decision-making and our therapeutics are designed with the patient foremost in mind. We continue to build a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding thereafter are what we call ‘another day at Turnstone’? If you are a passionate person, and our science excites you – this opportunity may be for you.

 

Summary:

We are seeking a highly effective, self-motivated, and versatile Quality Assurance professional with demonstrated knowledge of, and experience in, Quality Systems Management. As QA Associate you will support the team with a variety of systems including but not limited to: administration of our document management system and training program as well as support for change management, deviations/CAPAs, trending and Key Performance Indicators (KPIs). You will be responsible for ensuring that such systems and changes are supported in accordance with sound change management principles and Turnstone-defined procedures. This role is critical in maintaining a strong partnership with both our internal and external stakeholders in pursuit of advancing our pipeline. This role provides support remotely across all domestic time zones and reports into the Sr Manager for Quality Operations.

 

Responsibilities:

  • Administration of electronic systems such as Veeva and LearnGxP including supporting system updates, managing and administering training, and supporting document control activities.
  • Support the trending of quality systems such as deviation, change control, and CAPA programs as well as creates, owns, and manages deviations, change control requests, and CAPA records pertaining to their functional area.
  • Supports the Quality Operations function in evaluation and disposition of labelling, raw materials, intermediates and finished products through timely evaluation of batch records, laboratory results, and other GMP documents as needed.
  • Provide administrative support for audit program and quality agreements.
  • Reads, understands, and follows SOPs, and complies with GMP.
  • Writes new standard operating procedures or revises existing documentation utilizing document management systems.
  • Assists in the implementation of new processes.
  • Assists in assembling quality metrics and KPIs.
  • Identifies, coordinates, and implements continuous improvements.
  • Prioritizes day-to-day support for their functional area and longer-term projects or investigations.
  • Creates/revises QA documents (gap assessments, risk assessments, reports) in document management system.
  • Facilitates and coordinates training of new and existing team members, prepares training materials as necessary.
  • Represents QA, as needed, during meetings relevant to their functional area, communicates and tracks all follow-up items through to completion
  • Additional duties as assigned.

Education and Experience:

  • Bachelor’s in Biology, Engineering or science-related field preferred.
  • 2-4+ years industry experience, preferably in gene and cell therapy.
  • 2+ years of QA experience.
  • Experience in GMP environments including knowledge of change management principles and industry standard QMS applications.
  • Experience with Veeva, LearnGxP, DocuSign, SharePoint, SmartSheet are considered an asset.
  • Demonstrated ability to manage multiple tasks/projects with demanding timelines.
  • Strong interpersonal, teamwork, and organizational skills; effective oral and written communication skills.
  • Occasional travel to support cross-functional workshops or strategy/planning activities.

 

COMPENSATION

At Turnstone, we prioritize the well-being and success of our team. Join us and enjoy a competitive compensation package, including a base salary and performance-based bonuses. Our comprehensive benefits include:

 

  • Healthcare Coverage: Medical, dental, and vision insurance for you and your dependents.
  • Retirement Planning: 401(k) plan with employer contributions.
  • Time Off: Generous paid time off, including vacation, sick leave, and holidays.
  • Workplace Flexibility: Flexible schedules and remote work options.

To Apply:

Please click here to apply!

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process.  We thank all applicants for their interest, however, only those selected will be invited for an interview.

 

 

Contact

General Inquiries

info@turnstonebio.com

 

Partner
with Us

bd@turnstonebio.com

 

Talent Acquisition

hr@turnstonebio.com

 

Investors & Media

ir@turnstonebio.com

 

Clinical Trial Inquiries

ct@turnstonebio.com